Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavio Forrer

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Skeletal Radiology|May 23, 2013
4D-SPECT/CT in orthopaedics: a new method of combined quantitative volumetric 3D analysis of SPECT/CT tracer uptake and component position measurements in patients after total knee arthroplastyHelmut Rasch, Anna L Falkowski, Flavio Forrer, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 27, 2007
Neuroendocrine tumors. Peptide receptor radionuclide therapyFlavio Forrer, Roelf Valkema, Dik J Kwekkeboom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 22, 2015
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive MeningiomasKarine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, et al.
European Radiology|July 10, 2012
Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomographyGregor Sommer, Mark Wiese, Leopold Winter, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imagingFlavio Forrer, Edgar Rolleman, Magda Bijster, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller, Flavio Forrer, Bert F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomasFlavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, et al.
Journal of Neuro-Oncology|March 11, 2010
Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I studyDominik Cordier, Flavio Forrer, Stefan Kneifel, et al.
Contrast Media & Molecular Imaging|December 3, 2019
Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRIThomas Weikert, Ole Christopher Maas, Tanja Haas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2009
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry studyFlavio Forrer, Jianhua Chen, Melpomeni Fani, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Skeletal Radiology|May 23, 2013
4D-SPECT/CT in orthopaedics: a new method of combined quantitative volumetric 3D analysis of SPECT/CT tracer uptake and component position measurements in patients after total knee arthroplastyHelmut Rasch, Anna L Falkowski, Flavio Forrer, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 27, 2007
Neuroendocrine tumors. Peptide receptor radionuclide therapyFlavio Forrer, Roelf Valkema, Dik J Kwekkeboom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 22, 2015
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive MeningiomasKarine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, et al.
European Radiology|July 10, 2012
Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomographyGregor Sommer, Mark Wiese, Leopold Winter, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imagingFlavio Forrer, Edgar Rolleman, Magda Bijster, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller, Flavio Forrer, Bert F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomasFlavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, et al.
Journal of Neuro-Oncology|March 11, 2010
Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I studyDominik Cordier, Flavio Forrer, Stefan Kneifel, et al.
Contrast Media & Molecular Imaging|December 3, 2019
Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with <sup>90</sup>Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRIThomas Weikert, Ole Christopher Maas, Tanja Haas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2009
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry studyFlavio Forrer, Jianhua Chen, Melpomeni Fani, et al.
Pageof 4